EyePoint 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- EyePoint said its two Phase 3 wet AMD trials did not meet the primary endpoint in the analysis population.
- Across the trials, DuraView showed biological activity, vision improvement, reduced treatment burden, anatomic control measured by OCT, and a favorable safety profile with repeat dosing.
- In pooled analysis, more than 50% of DuraView-treated patients who went supplement-free through week 56 showed nominal non-inferiority in mean change in BCVA versus on-label 2 mg of Libercept control.
- In the Phase 2 VERONA study, DuraView and aflibercept had equivalent vision improvement, while DuraView showed greater reduction in CST and leakage; 73% of DuraView patients remained free of supplemental anti-VEGF injections through week 24 versus 50% of aflibercept controls.
- EyePoint ended September 30th, 2026 with approximately $118 million in cash, cash equivalents, and investments in marketable securities.
- The company discontinued its Phase 3 wet AMD program and announced a workforce reduction of approximately 53%, expected to generate $30 million in annualized savings once fully implemented.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning. My name is Didi, and I'll be your conference operator today. At this time, I would like to welcome everyone to the EyePoint third quarter 2026 financial results and recent corporate developments conference call. There will be a question-and-answer session to follow at the completion of the prepared remarks. Please be advised this call is being recorded at the company's request. I would now like to turn the call over to George Elston, Executive Vice President and Chief Financial Officer of EyePoint.
Sir, please go ahead. Thank you, and thank you all for joining us on today's conference call to discuss EyePoint's third quarter 2026 financial results and recent corporate developments.
With me today is Dr. Jay Duker, President and Chief Executive Officer of EyePoint. Jay will begin with a review of recent corporate updates and discuss our clinical program for DURAVYU in DME and the results from the wet AMD program. I will close with commentary on the third quarter 2026 financial results. We will then open the call for your questions, where we will be joined by Dr. Ramiro Ribeiro, our Chief Medical Officer, Mike Campbell, our Chief Commercial Officer, and Dr. Tarek Hassan, our Chief Strategic Science Officer. Earlier this morning, we issued a press release detailing our financial results and recent corporate developments. A copy of the release can be found in the Investor Relations tab on the company website, www.eyepoint.bio.
Before we begin our formal comments, I'll remind you that various remarks we make today constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. These include statements about our future expectations, clinical developments, and regulatory matters and timelines, the potential success of our products and product candidates, financial projections, and our plans and prospects. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the risk factor section of our most recent annual report on Form 10-K, which is on file with the SEC, and in other filings that we have made or may make with the SEC in the future. Any forward-looking statements represent our views as of today only.
While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our views change. Therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today. I'll now turn the call over to Dr. Jay Duker, President and Chief Executive Officer of EyePoint.
Thank you, George. Good morning, everyone, and thank you for joining us. This has been an eventful quarter for EyePoint, and I want to begin with what is top of mind for all of us. This past August and October, we announced that our two phase III wet AMD clinical trials did not meet the primary endpoint in the full analysis population. We are deeply disappointed with this result. At the same time, these two studies generated important clinical findings about DURAVYU. Across both trials, DURAVYU consistently demonstrated biological activity as well as vision improvement, superior reduction in treatment burden, anatomic control as measured by OCT, and a favorable safety profile with repeat dosing. In the pooled analysis of both trials, the greater than 50% of DURAVYU-treated patients who went supplement-free up to week 56 manifested nominal non-inferiority in mean change in BCVA versus on-label two milligram of Eylea control.
These studies confirm that DURAVYU is active and could potentially play a role in exudative retinal disease. Following LUCIA, we acted quickly to align the organization around the program where we believe additional resources are justified by both the evidence and the potential for improving patient care. As previously mentioned, to preserve our cash runway, we are discontinuing the wet AMD program, reducing our workforce by approximately 53%, and significantly reducing our operating cost structure moving forward. Our main clinical priority now is diabetic macular edema, or DME. There are several reasons to believe DURAVYU could perform differently in DME than it did in wet AMD. Our confidence in COMO and CAPRI rests on the following points. DME and wet AMD are biologically distinct diseases.
Wet AMD is primarily caused by macular neovascularization, or the growth of abnormal blood vessels from the choroid, with VEGF playing the central role in driving angiogenesis and vascular leakage. DME, in contrast, develops from diabetes-related injury to the retinal microvasculature and breakdown of the blood-retinal barrier due to inflammation, hyperglycemia, and other factors that result in the leakage. Intraocular biomarker data reflects this difference. Unlike in wet AMD, patients with DME typically show elevated IL-6 levels. IL-6 signaling acts not only as a biomarker, but is linked to inflammation, retinal vascular dysfunction, and the breakdown of the blood-retinal barrier. Previously presented clinical data suggests that blocking both IL-6 and VEGF can potentially give better results than blocking VEGF alone in DME patients. This is directly relevant to DURAVYU because vorolanib inhibits all VEGF isoforms, the PDGF receptor, and JAK1, a key mediator of IL-6 signaling.
Our published preclinical work demonstrates a greater than 50% reduction in IL-6 activity through JAK1 inhibition. Thus, DURAVYU has the potential to address both VEGF-driven vascular permeability and IL-6-driven inflammation with one therapy. Further evidence comes from the fact that intraocular corticosteroids effectively treat DME, but with minimal benefit in wet AMD. Studies in pseudophakic eyes demonstrate that corticosteroids exhibit similar activity to anti-VEGF biologics, despite corticosteroids acting primarily through anti-inflammatory mechanisms. EyePoint's phase II VERONA data showed equivalent vision improvement for DURAVYU and aflibercept, but DURAVYU eyes had superior reduction in CST as well as leakage, as measured by fluorescein angiography. In VERONA, 73% of DURAVYU patients remained supplement-free of anti-VEGF injections through week 24, versus 50% of the aflibercept controls. DURAVYU also demonstrated rapid efficacy, with four to five letters of vision improvement and an approximately 50-micron improvement in CST compared to aflibercept at week four.
We believe this early improvement for patients, if confirmed in the phase III trials, will be important. We now have substantial clinical experience with DURAVYU in about 450 patients from the wet AMD phase III trials, demonstrating pharmacologic activity, durability, and safety with repeat dosing. The extensive safety experience is an important component in our confidence in DURAVYU going forward. Sustained release may be particularly advantageous for DME, as nearly 50% of patients discontinue treatment within six months. Patient age, comorbidities, treatment burden, and delayed perceived benefit contribute to undertreatment in the real world. We believe DURAVYU's potential to deliver earlier improvement with fewer injections could offer a compelling treatment profile. Taken together, the rationale for DURAVYU in DME rests on these points: the distinct biology of DME, our compelling VERONA data, and extensive DURAVYU's clinical experience showing fluid control and safety with repeat dosing.
With a unique multi-mechanism of action, robust clinical data package, proven delivery technology, the ability to be shipped and stored at ambient temperatures, and administration via a standard intravitreal injection, DURAVYU represents a compelling and innovative product profile that has the potential to meaningfully change the treatment paradigm in DME, a $5 billion global market that includes $3 billion in the U.S. We expect to announce top-line results from both COMO and CAPRI, which enrolled over 550 patients, early in the fourth quarter of 2027. Our organization is focused on execution and delivering these results next year in order to maximize value for our shareholders and further our mission to improve the lives of patients with serious retinal diseases. Before passing it over to George to review our financials, I'd like to thank the entire EyePoint team for their commitment and perseverance to our mission.
We are grateful to the study participants, study coordinators, and clinical investigators who enable our research. I will now turn the call over to George.
Thank you, Jay. As the financial results for the three months ended September 30, 2026, were included in the press release issued this morning, my comments today will address the actions we are taking to align our cost structure with our strategic priorities and preserve our financial flexibility. As previously announced, we ended September 30, 2026, with approximately $118 million in cash equivalents, and investments in marketable securities. We expect this runway to fund operations into late Q3 2027, excluding any potential cash flows from business development or financing activities that we may undertake or other operational savings and adjustments presently under active review. Capital discipline is now one of our highest priorities. Our objective is to preserve the resources required to obtain the pivotal DME data while delivering COMO and CAPRI to the utmost standard.
We have multiple levers available to us to further extend our financial runway, and we are actively evaluating those opportunities to preserve strategic flexibility and maximize long-term shareholder value. Following the results of the LUCIA trial, we took decisive action to focus our financial and operational resources on the continued development of DURAVYU in DME. As part of this prioritization, we announced a workforce reduction of approximately 53%, generating $30 million in annualized savings once fully implemented, and the discontinuation of the phase III wet AMD program. These actions are intended to align our operating expenses with a more focused organization and development strategy. Our priorities are straightforward: execute COMO and CAPRI with the rigor required of pivotal clinical studies, carefully manage our financial resources, and maintain flexibility as we approach the next major clinical milestone. I will now turn the call back over to Jay for closing remarks.
Thank you, George. We believe DURAVYU represents a potentially meaningful and valuable opportunity in DME, supported by compelling clinical evidence and strong scientific rationale. With our strategic priorities clearly defined and our resources focused on DME, we are committed to advancing this important program by delivering on the next clinical milestone, maintaining financial discipline, and creating long-term value for our shareholders. Thank you all for your attention this morning. I will now turn the call over to the operator for questions.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
15 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
